TL1A contributes to the pathogenesis of several chronic inflammatory diseases, including those of the bowel by enhancing T H 1, T H 17, and T H 2 responses. TL1A mediates a strong costimulation of these T H subsets, particularly of mucosal CCR9 + T cells. However, the signaling pathways increased IL-9 production by peripheral T H 17 cells isolated from patients with Crohn's disease. These data suggest that TL1A differentially induces expression of T H 17 effector cytokines IL-17, -9, and -22 and provides a potential target for therapeutic intervention in T H 17-driven chronic inflammatory diseases.
Introduction
TL1A, a member of the TNF superfamily, and its receptor DR3 are up-regulated during chronic intestinal inflammation in UC and CD and in mouse models of chronic intestinal inflammation [1] [2] [3] [4] [5] . Its expression is mainly confined to inflamed tissues of the colon and small bowel. Both TL1A and its receptor DR3 are particularly highly expressed on gut-homing CD4 + CCR9 + mucosal T cells [1, 6] . Its expression is also markedly enhanced in lamina propria macrophages from patients with CD [5] . TNFSF15, the gene encoding TL1A, has been identified as a susceptibility and severity gene in IBD by genome-wide association studies [7] . We have demonstrated that patients with CD who carry a TNFSF15 risk haplotype have higher TL1A protein expression by peripheral blood monocytes and develop significantly more intestinal strictures and worse inflammation in the ileocolonic region [8, 9] . We, and others, have shown that transgenic mice that overexpress TL1A in the myeloid or lymphoid compartment develop small-intestine inflammation and fibrosis that are characterized by overexpression of IFN-g, IL-17, and IL-13 [8, 10, 11] . On the contrary, administration of neutralizing TL1A antibodies attenuates chronic colitis by affecting both T H 1 and T H 17 responses, which suggests that it is a major regulator of intestinal inflammation during colitis [12] . It promotes proliferation of T cells and augments IFN-g production by T H 1 cells and IL-17 production by T H 17 cells [6, [12] [13] [14] [15] [16] . It exerts its biologic effects by binding to its receptor DR3, which is primarily expressed on activated T cells, resulting in the activation of the NF-kB and MAPK signaling pathways [17, 18] .
Although compelling in vivo data endorse a role for TL1A in promoting T H 17 differentiation and effector function, its role in the differentiation of T H 17 cells in vitro is still controversial [19] . It is undisputed that it enhances the secretion of IL-17 in effector T cells, but it has been demonstrated that it can inhibit human and murine T H 17 differentiation in vitro by mechanisms that are independent of STAT1 and IL-2 signaling [20] . The exact inhibitory signaling mechanisms of TL1A during the differentiation of naïve T cells into T H 17 cells and the stimulatory signaling pathways engaged by it in memory T cells and committed T H 17 cells remain to be elucidated.
In this study, we investigated the effect of TL1A on cytokine secretion by committed peripheral human T H + human T H 17 cells, whereas IL-17 secretion was not affected in these cells. It did not affect transcriptional levels of the transcription factor AhR, which regulates the expression of IL-22, suggesting a signaling pathway of TL1A-induced IL-22 that is independent of AhR. We performed transcriptome analysis of TL1A-stimulated T H 17 cells and identified IL-22 and IL9 as genes with the highest induction by TL1A. It significantly induced IL-9 secretion in T H 17 cells in a dosedependent manner. Blocking IL-9 receptor antibodies completely abrogated the TL1A-induced IL-22 secretion in T H 17 cells. Furthermore, TL1A significantly induced the secretion of IL-9 but not of IL-17 in peripheral T H 17 cells isolated from patients with CD. Our data suggest that TL1A is an important immune modulator in human T H 17 cells and leads to the induction of IFN-g, IL-9, and IL-22 in these cells, increasing their proinflammatory propensity. TL1A therefore represents an attractive interventional target in chronic T H 17-driven inflammatory diseases.
MATERIAL AND METHODS

Isolation of CD4
+ T cells from PBMCs and cell sorting 
T cell stimulation
T cells were stimulated with immobilized anti-CD3 (5 mg/ml; BD Biosciences) and anti-CD28 (2 mg/ml; Bristol-Myers Squibb, New York, NY, USA) in the presence of TGF-b1 (3 ng/ml; PeproTech, Rocky Hill, NJ, USA), IL-6 (50 ng/ml; PeproTech), IL-23 (20 ng/ml; R & D Systems, Minneapolis, MN, USA), TL1A (100 ng/ml; Fitzgerald Industries International, Acton, MA, USA), and neutralizing antibodies to IL-4 (2 mg/ml) and IFN-g (3 mg/ml; BioLegend, San Diego, CA, USA) for 3 days, or as indicated. In selected experiments, blocking antibodies to IL-9 receptor (BioLegend) or isotype controls were added at the time of stimulation.
Quantitative real-time PCR analyses T-bet (probe: TCC GCC GTC CCT GCT TGG  TGA TGA, forward: CCA AGT TTA ATC AGC ACC AGA CAG, reverse: GCC  ACA GTA AAT GAC 
ELISA
Human IL-17A, IFN-g, IL-9 (all eBioscience), and IL-22 (R&D Systems) were quantified with ELISA kits.
Flow cytometry
For the detection of intracellular cytokines, cultured cells were stimulated with PMA (50 nM), ionomycin (1 mg/ml), and monensin (eBioscience) for 4 h at 37°, or monensin was added for the last 4 h of stimulation. Cells were harvested and stained for CD4 and intracellular IL-17 (Alexa Fluor 647-IL-17), IFN-g (FITC-IFN-g), IL-9 (eFluor 660-IL-9) (all eBioscience), IL-22 (PE-IL-22; R&D Systems), or isotype controls, with the Fixation and Permeabilization kit (eBioscience). For selected experiments cells were stained with DR3, CCR6 (both eBioscience), CCR9, CXCR3 (both R&D Systems), CCR3 (BD Bioscience), and IL-9. For the analysis of cell proliferation, cells were stained for CD4, IL-9, and Ki67 (eFluor450-Ki67, eBioscience). For the analysis of apoptosis, cells were harvested according to the manufacturer's instructions and stained with annexin-V (APC-annexin-V) and Fixable Viability dye (eFluor 780; both eBioscience) and acquired within 2 h. Cells were acquired on a CyAnTM ADP flow cytometer (Dako, Carpinteria, CA, USA) and analyzed with FlowJo software (TreeStar Inc., Ashland, OR, USA).
Gene expression analysis
RNA was isolated from stimulated T cells at the indicated time points with the RNeasy Micro kit (Qiagen). cRNA amplification and biotin labeling were performed with 500 ng total RNA using the Illumina TotalPrep RNA Amplification Kit (ThermoFisher Scientific). cRNA yield was determined with a NanoDrop spectrophotometer (NanoDrop Technologies, Wilmington, DE, USA), and 1.5 mg biotin-labeled cRNA was hybridized onto HumanHT-12_V4 Expression Beadchips (Illumina, San Diego, CA, USA) and scanned with the Illumina iScan according to the manufacturer's protocol. All samples from 5 independent experiments were run together at the same time under identical conditions. Data visualization and quality control were performed with the Gene Expression module v1.9.0 of GenomeStudio v2011.1 software (Illumina). Data were normalized and analyzed using BRB-Array Tools (Version 4.4.0; http://brb.nci.nih.gov/BRB-ArrayTools/; NIH, National Cancer Institute, Frederick, MD, USA). Hierarchical clustering of total array data and class comparison between control and TL1A-treated cells were performed with the BRB-Array Tools. Detection at P , 0.01 was tagged as significant expression and used for analysis. Ingenuity software (Qiagen) was used for gene pathway and function analysis. Microarray expression data for GSE89133 are publicly available at the Gene Expression Omnibus (GEO) repository (http://www.ncbi. nlm.nih.gov/geo/query/acc.cgi?acc=GSE89133).
Statistics
Statistical significance was determined by Student's t test. P , 0.05 indicated statistical significance.
RESULTS
TL1A enhances IL-17 production by human CD45RO + memory T cells
We and others have demonstrated that TL1A is a strong costimulator of T H 1 responses [4, 6, 15] . However, its effect on significantly enhanced IFN-g secretion, whereas stimulation with TGF-b, IL-6, and IL-23 had no effect on it (Fig. 1B) . When we analyzed the secretion of IL-22, we observed that TL1A alone led to maximum secretion of IL-22 in CD4 + CD45RO + memory T cells (Fig. 1C) . In contrast, TGF-b suppressed IL-6-and TL1A-induced IL-22 secretion by CD4
+ CD45RO + cells, consistent with previously reported data [22] . To understand the molecular mechanisms by which TL1A enhances IL-17 and IFN-g production by human CD4 + CD45RO + T cells, we analyzed the expression of the T H 17 transcription factors BATF and the T H 1 transcription factor T-bet. BATF has been described as a pioneer transcription factor for the differentiation of T H 17 cells [23, 24] . Analysis of the expression of BATF revealed that a combination of TGF-b, IL-6, IL-23, and TL1A led to maximum induction of BATF mRNA (Fig. 1D) . In contrast, TL1A alone significantly increased the expression level of the T H 17 transcription factor RORgt (encoded by the human gene RORC), but did not further increase RORgt expression when stimulated with TGF-b, IL-6, and IL-23 (Supplemental Fig. 1A) . Similarly, it significantly increased the expression of RORA, a transcription factor that is essential for T H 17 differentiation, but did not further increase RORA expression when stimulated with TGF-b, IL-6, and IL-23 [25] . Stimulation with TL1A in combination with TGF-b, IL-6, and IL-23 also led to maximum induction of T-bet mRNA ( 1B) . We observed an up-regulation of DR3 expression in the presence of TGF-b and IL-6 compared to the level in unstimulated cells (Supplemental Fig. 1C) . However, neither IL-23 nor TL1A could further increase the expression of DR3, suggesting that the increase in IL-17 and IFN-g production in the presence of TL1A is not due to higher DR3 expression.
TL1A increases IL-22 production in committed T H 17 cells
It has been said that human peripheral CD45RO + CCR6 + cells are committed T H 17 cells [26, 27] . To determine whether TL1A could enhance the production of IL-17 from committed T H 17 cells, we isolated human CD45RO + CCR6
+ cells from peripheral blood and stimulated them with TL1A for 3 d. Stimulation of T H 17 cells with TL1A did not significantly enhance the secretion of IL-17 compared to that in unstimulated cells ( Fig. 2A) . We also did not observe an effect of the stimulation on the expression level of RORC (Fig. 2B ), supporting our observation that TL1A does not induce IL-17 expression in committed T H 17 cells. However, we observed an enhancement of IFN-g production by TL1A alone in committed T H 17 cells, but it did not reach significance (Fig. 2C) . In contrast, it significantly increased the secretion of IL-22 (Fig. 2D) . Similar to our observation in memory T cells, TL1A did not overcome the suppression of IL-22 secretion induced by TGF-b. To determine the time-course of IFN-g and IL-22 secretion in response to TL1A, we stimulated committed T H 17 cells for different time points in a larger cohort of human volunteers. TL1A alone significantly increased the secretion of IFN-g at 24 and 48 h of stimulation by 1.6-and 1.5-fold, respectively (Fig. 2E) . Furthermore, TL1A alone significantly increased the secretion of IL-22 at different time points, starting as early as 6 h post stimulation up to 72 h of stimulation (4.3-, 2.1-, 2.0-, and 1.8-fold, for 6, 24, 48 , and 72 h, respectively) (Fig. 2F) . The expression of IL-22 is regulated by the transcription factor AhR [28] . To elucidate the mechanism of TL1A-induced expression of IL-22 in T H 17 cells, we analyzed the expression of AhR at different time points. We did not observe significant changes in expression of AhR mRNA in response to TL1A stimulation at 24 or 48 h, suggesting that TL1A induces IL-22 via AhR-independent pathways (Fig. 2G ).
Increased IL-22 production in committed T H 17 cells by TL1A stimulation is driven by IL-9 secretion
To determine the mechanism of TL1A-induced IL-22 production in T H 17 cells, we performed global gene expression analysis of TL1A-stimulated T H 17 cells (Fig. 3A, B ; Supplemental Fig. 2A , Supplemental Table 1 ). Unsupervised clustering analysis did not show significant differences between controls and TL1A-treated cells but showed clustering at the different time points. A heat map visualization at the different time points revealed genes with expression that differed by at least 1.5-fold in T H 17 cells stimulated with TL1A vs. controls (Fig. 3A) . Among the genes that demonstrated the highest up-regulation in TL1A-stimulated T H 17 cells at all time points analyzed (24, 48, and 72 h) were IL-22 and IL-9 (Fig. 3B) . We also confirmed the induction of IFN-g (24 h time point) at a lower fold increase than IL-9 and 2B , and data not shown). Because IL-9 has been described as a T H 17-associated cytokine, we hypothesized that the induction of IL-9 by TL1A would lead to the up-regulation of IL-22. First, we confirmed our gene array data by quantitative real-time PCR. IL-9 mRNA expression was induced early on in TL1A-stimulated T H 17 cells and remained up-regulated for up to 72 h (Fig. 4A) . Next, we confirmed TL1A-induced IL-9 secretion in T H 17 cells. We observed a dose-dependent increase in IL-9 secretion after stimulation with TL1A at 24 and 48 h (Fig. 4B) . Similar to the induction of IL-22 by TL1A in T H 17 cells, we observed that TL1A alone is a strong inducer of IL-9, particularly at early time points (Fig. 4C) . Furthermore, we observed synergistic induction of IL-9 under T H 17 and TL1A stimulation (Fig. 4C) . Concomitant with the dose-dependent increase of IL-9 secretion by TL1A stimulation we observed an increase in IL-9 + , IL-22 + , and IL-9 + IL-22 + cells, as detected by intracellular cytokine staining (Fig. 5A) . We observed a significant increase in the percentage of IL-9 + cells with a concentration of 100 ng/ml of TL1A at 24 and 48 h of stimulation (Fig. 5B) .
On a per-cell basis, IL-9 output (as measured by mean fluorescence intensity) was higher in TL1A-stimulated cells that reached significance for the highest TL1A concentration used (Supplemental Fig. 3A ), suggesting that TL1A induces IL-9 expression and enhances the IL-9 output by IL-9-producing cells. We confirmed the time course of IL-9 secretion by T H 17 cells in response to TL1A in a large cohort of human healthy volunteers. TL1A alone significantly increased the secretion of IL-9 at 24 and 48 h after stimulation by 3.2-, and 2.6-fold, respectively (Fig. 5C) Fig. 3B ). We observed a population of Ki67 2 IL-9-producing cells in control and TL1A conditions, suggesting that proliferation was not necessary for IL-9 production (data not shown). Next, we analyzed the degree of apoptosis in T H 17 cells treated with TL1A. We did not observe an overall increase in annexin-V + cells in TL1A-treated T H 17 cells (Supplemental Fig. 3C ).
However, because of the incompatibility of annexin-V and intracellular IL-9 staining, we were unable to distinguish whether apoptotic cells belong to the IL-9 + or IL-9 2 subpopulations. These data suggest that TL1A induces the expression of IL-9, rather than leading to a preferential proliferation of IL-9-producing cells. To prove our hypothesis that TL1A-induced secretion of IL-22 is dependent on IL-9, we used anti-IL-9R blocking antibodies. In agreement with our hypothesis, we observed a dose-dependent inhibition of TL1A-induced IL-22 (Fig. 5D) . We observed similar results with neutralizing anti-IL-9 antibodies (data not shown). These data demonstrate that TL1A induces IL-22 in T H 17 cells via the early induction of IL-9.
We performed intracellular cytokine staining to further characterize the phenotype of IL-9-producing cells. Only 8.6% + cells were also IL-17 + cells, and 39.5% of all IL-9 + cells were also IFN-g + cells (Fig. 6A) . TL1A increased the percentage of IFN-g + IL-9 + cells, whereas the percentage of IFN-g + cells did not change in the presence of TL1A. Next, we analyzed the chemokine receptor profile of IL-9 producing T H 17 cells. We did not observe expression of CCR6, CCR9, CXCR3, or CCR3 on IL-9 + cells (Supplemental Fig. 4A-D) .
TL1A increases IL-9 production in committed T H 17 cells isolated from patients with CD
The expression of TL1A is increased in patients with CD and has been implicated in disease pathogenesis. To assess whether it increases the expression of IL-9 in T H 17 cells from patients with CD, we isolated T H 17 cells from peripheral blood of affected patients. Consistent with our data from healthy donors, TL1A significantly up-regulated IL-9 secretion in T H 17 cells isolated from patients with CD (2.7-and 3-fold increase for 48 and 72 h, respectively) ( Fig. 6B; Supplemental Fig. 4E ). In contrast, it did not significantly increase the secretion of IL-17. We also observed an increase in IL-22 (average: 1.7-fold increase) and IFN-g (average: 2.0-fold increase) secretion upon stimulation with TL1A. Intracellular staining confirmed an increase in the percentage of IL-9 + cells upon stimulation (Fig. 6C) . Taken together, these data show that TL1A increases the secretion of IL-9 but not of IL-17 in peripheral T H 17 cells from patients with CD.
DISCUSSION
TL1A, a member of the TNF superfamily, has been implicated in the pathogenesis of IBD. Genome-wide association studies have identified TNFSF15 (the gene encoding TL1A) as an IBD susceptibility and severity gene [29] . Patients with CD carrying a TNFSF15 risk haplotype overexpress TL1A and are more prone to intestinal fibrosis [7, 30] . TL1A promotes T H 1 responses and has also been implicated in T H 17 responses, but the data demonstrating the role of TL1A in the differentiation of T H 17 cells have been conflicting [19, 20, 31] , and the signaling pathways engaged by TL1A during the differentiation of T H cells have not been clearly defined.
In the current study, TL1A greatly increased the secretion of the T H 17 cytokines IL-17A, IL-22, and the T H 1 cytokine IFN-g from memory CD4
+ T cells. TL1A also induced IL-22, IL-9, and IFN-g from committed human T H 17 cells isolated from healthy controls and patients with CD. The T H 17 pathway has been linked to several inflammatory diseases, including colitis, psoriasis, arthritis, and experimental autoimmune encephalomyelitis [32] . It has been demonstrated that TL1A plays an important role in T H 17-mediated diseases, including autoimmune encephalomyelitis and chronic colitis [12, 16] . We analyzed the expression of T H 17/T H 1-driving transcription factors and observed that TL1A induces high expression of BATF and T-bet, correlating with high expression of IL-17 and IFN-g in these conditions. BATF and IRF4 have been proposed as "pioneer factors" in the differentiation of T H 17 cells by contributing to the initial chromatin accessibility and facilitating the access of other transcription factors [33] . We observed that TL1A synergized with TGF-b, IL-6, and IL-23 to induce maximum BATF expression in memory CD4 + T cells. TL1A alone increased the expression of the T H 17 transcription factors RORA and RORC, but did not further enhance their expression in response to TGF-b, IL-6, and IL-23 stimulation. Our data suggest that the induction of T-bet and BATF by TL1A may lead to the secretion of IFN-g and IL-17A in memory T cells, respectively. + T H 17 cells were stimulated with anti-CD3, anti-CD28, and TL1A in the presence of blocking IL-9 receptor antibodies or isotype controls for 2 days. Supernatants were analyzed for IL-22 by ELISA. The secretion of IL-22 in anti-IL-9 receptor antibodies or isotype control-treated cells was compared to TL1A-stimulated cells (set at 100% of IL-22 secretion). Data represent the means of duplicates 6 SD. One representative experiment of 3 (A, D) with similar results is shown. *P , 0.05, **P , 0.01.
TL1A induces a cell type of IL-17/IFN-g coproducing T H 17 cells a phenotype that has been defined as a pathogenic T H 17 subtype [34] . Recent data derived from TL1A 2/2 mice further suggest that TL1A plays an essential role in the optimal differentiation as well as effector function of murine T H 17 cells [16] . We observed strong increases of IL-22 in memory CD4 + T cells and committed human T H 17 cells induced directly by TL1A without the need for costimulation by additional cytokines. In contrast to memory CD4 + T cells, TL1A had no effect on IL-17 production in committed T H 17 cells isolated from healthy donors or patients with CD, suggesting a differential regulation by TL1A of IL-22, IL-9, and IFN-g on the one hand and IL-17 on the other. Our data are consistent with recent findings of differential regulation of IL-22 and IL-17 in human T cells [35] . Although IL-6 alone induces IL-22, the combination of TGF-b and IL-6 results in the production of IL-17 but not IL-22 in T cells. We observed that TL1A alone was a stronger inducer of IL-22 than IL-6 in memory CD4 + T cells and in committed T H 17 cells.
Recently, a population of memory T cells has been described that produce IL-22 but neither IL-17 nor IFN-g [36, 37] . TL1A stimulation did not affect the transcriptional levels of AhR, a transcription factor that regulates IL-22 production in CD4 + T cells, suggesting that TL1A induces IL-22, independent of AhR in T H 17 cells [38, 39] . Indeed, transcriptional profiling of human T H 17 cells stimulated with TL1A identified IL-9 as a cytokine highly induced by TL1A in these cells. Mechanistically, we demonstrated that blocking antibodies to IL-9 receptor-attenuated TL1A induced secretion of IL-22 in T H 17 cells. Although TL1A has been shown to increase proliferation in T cells, we did not observe any significant changes in proliferation in IL-9 + or total T H 17 cells, suggesting that it induces the expression of IL-9 rather than leading to a preferential proliferation of IL-9 producing cells. Similar to the induction of IL-17/IFN-g coproducing cells by TL1A, we observed that it induced IL-22/IL-9-and IFN-g/IL-9-coproducing cells. IL-9 and T H 9 cells have been associated with the pathogenesis of IBD, particularly in UC. IL-9 + CD4 + T cells were enriched in the intestinal mucosa of patients with UC [40, 41] , and mice with IL-9-deficiency were protected from intestinal inflammation in a mouse model of UC [40] . In the current study, peripheral T H 17 cells from patients with CD were also producing IL-9, and TL1A significantly increased IL-9 secretion of these cells. Recently, it has been demonstrated that TL1A enhances IL-9 secretion of murine T H 9 cells but TL1A-induced secretion of IL-9 in other T H subsets was not reported in that publication [42] . Our data suggest that TL1A exerts its proinflammatory effects in vivo on multiple levels by inducing not only IL-17, but also IFN-g, IL-9, and IL-22 in memory T cells and IL-22, IL-9, and IFN-g in committed T H 17 cells. Although we did not observe an increase in IL-17 by TL1A in T H 17 cells from healthy donors or patients with CD, the induction of IL-9, IFN-g, and IL-22 by TL1A may render these cells more pathogenic in vivo. Our data provide important insights into the effector function of human T H 17 cells and have implications for the understanding and potential therapeutic manipulation of T H 1/T H 17-associated diseases. Clinical trials using anti-IL-17 neutralizing antibodies in patients with CD have failed to show a beneficial effect [43, 44] . On the contrary, some patients receiving anti-IL-17 antibodies developed more severe inflammation. These patients were carriers of a TL1A (TNFSF15) risk polymorphism, and their adverse response to anti-IL-17 antibodies may have been related to higher mucosal TL1A expression, suggesting an important TL1A-IL-17 network in patients with CD [43] .
Although IL-17 and -22 have been initially described to be produced by T H 17 cells, both cytokines exert distinct in vivo functions. IL-22 has been implicated in epithelial cell homeostasis, tissue repair, and wound healing, and a different regulation between IL-17 and -22 has been suggested [35] . Our data confirm and extend a different regulation between IL-17 and -22 production, depending on the T cell subtype (memory T cell and T H 17 cells) and the cytokines used for in vitro stimulation. Although TL1A alone induces IL-22 secretion in memory T cells and T H 17 cells, TL1A requires the presence of TGF-b, IL-6, and IL-23 for enhanced secretion of IL-17 by memory T cells and is unable to enhance IL-17 secretion by T H 17 cells. IL-22 has been shown to be protective in mouse models of IBD by inducing antimicrobial peptides and promoting tissue repair [45] . Conversely, deregulated IL-22 signaling contributes to the pathogenesis of IBD and colon cancer, and although IL-22 exerts a protective effect, elevated levels have been seen in the mucosa of patients with IBD and colon cancer [46] [47] [48] . IL-22 and -9 have seemingly opposing direct effects on intestinal epithelial cells. IL-9 directly impairs intestinal barrier function and prevents mucosal wound healing in mice by regulating the expression of tight junction proteins and epithelial cell proliferation [40] . However, in colorectal cancer, IL-22 + cells promote cancer stemness and correlate negatively with patient outcome [47] . The expression of the TL1A receptor DR3 is high on activated T cells and on committed human T H 17 cells and also on ILCs [20, 48, 49] . Indeed, murine and human ILC3s respond to stimulation with IL-23 and TL1A or IL-23, IL-1b, and TL1A with increased expression of IL-22 [48, 50] . However, although we observed a direct effect of TL1A on IL-22 secretion in memory CD4
+ T cells and committed T H 17 cells, in ILCs, TL1A alone did not induce IL-22 and needed IL-23 for its induction, suggesting different signaling pathways in CD4 + T cells and ILCs [48, 50] . The lack of TCR signaling in ILCs may explain the different requirements for IL-22 secretion by TL1A. A recent publication demonstrating IL-22 secretion by TL1A requiring the costimulation of IL-15 under TCR-independent conditions supports this notion [51] . These published findings and our current data suggest that TL1A is a strong inducer of IL-22 in T cells and ILCs and that IL-22 derived from both cell populations contribute to the pathologies in IBD. Prior publications have demonstrated that TL1A suppresses the differentiation of naïve CD4 + T cells into T H 17 cells by enhancing the production of IL-2, which acts as a negative regulator of T H 17 differentiation [16, 20] . In contrast, TL1A enhanced IL-17 expression in activated murine CD4 + T cells by mechanisms independent of its ability to enhance proliferation [20] . Our data confirm and extend these findings, demonstrating that TL1A induces IL-17 expression in human effector/memory CD4 + T cells. Furthermore, it induced multiple T H 17-associated cytokines, including IL-22, IL-9, and IFN-g in T H 17 cells isolated from healthy controls and from patients with CD. Collectively, these results support the view that TL1A's activities depend on the activation status of the T cell population and that it differentially regulates different cytokines. 
